

Causes of death in low-grade B-cell lymphomas in the rituximab era: a prospective cohort study

Aung M. Tun,^{1,2} Arushi Khurana,¹ Raphael Mwangi,³ Brian K. Link,⁴ Yucai Wang,¹ Andrew L. Feldman,⁵ Carrie A. Thompson,¹ Anne J. Novak,¹ Jose C. Villasboas,¹ Gita Thanarajasingam,¹ Umar Farooq,⁴ Sergei Syrbu,⁶ Grzegorz S. Nowakowski,¹ Thomas E. Witzig,¹ Stephen M. Ansell,¹ Lisa M. Rimsza,⁷ James R. Cerhan,³ Thomas M. Habermann,^{1,*} and Matthew J. Maurer^{3,*}

¹Division of Hematology, Mayo Clinic, Rochester, MN; ²University of Kansas Cancer Center, University of Kansas, Kansas City, KS; ³Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN; ⁴Division of Hematology, Oncology, and Blood & Marrow Transplantation, University of Iowa, Iowa City, IA; ⁵Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN; ⁶Department of Pathology, University of Iowa, Iowa City, IA; and ⁷Department of Laboratory Medicine and Pathology, Mayo Clinic, Scottsdale, AZ

Key Points

- Mortality for patients with marginal zone and indolent B-cell lymphoma is largely unrelated to lymphoma in the first decade from diagnosis.
- Early progression or retreatment within 24 months of diagnosis is strongly associated with increased risk of lymphoma-related mortality.

Low-grade B-cell lymphomas other than follicular and small lymphocytic lymphoma (LGBCL) account for 10% of all B-cell non-Hodgkin lymphomas. Despite improvements in survival outcomes for these patients, little is known about cause of death (COD) in the rituximab era. For a better understanding, we studied 822 newly diagnosed patients with marginal zone, lymphoplasmacytic, and unclassifiable low-grade B-cell lymphoma prospectively enrolled in the University of Iowa/Mayo Clinic Specialized Program of Research Excellence Molecular Epidemiology Resource from 2002 to 2015. COD was assigned based on medical record review using a standard protocol. At a median follow-up of 107 months, 219 (27%) patients had died. The incidence of lymphoma-related deaths when pooling across subtypes was lower than non-lymphoma-related deaths (10-year incidence, 8.0%; 95% confidence interval [CI]: 6.2-10.4 vs 13.6%; 95% CI: 11.2-16.6). The incidence of lymphoma-related deaths varied by subtype, ranging from 3.7% at 10 years in extranodal marginal zone lymphoma to 19.3% in lymphoplasmacytic lymphoma/Waldenström macroglobulinemia. Patients with early progression or retreatment events, defined using event-free survival at 24 months from diagnosis, had significantly higher likelihood of lymphoma-related death compared with patients without early events (10-year estimate: 19.1% vs 5.1%, respectively; $P < .001$), whereas the rates for non-lymphoma-related death were comparable in patients with or without early events (10-year estimates: 11.0% vs 15.3%, respectively). In conclusion, the most common COD in LGBCLs in the first decade after diagnosis was for causes other than lymphoma. Progression or retreatment within the first 2 years of diagnosis was a strong predictor for risk of lymphoma-related death.

Submitted 2 May 2022; accepted 9 July 2022; prepublised online on *Blood Advances* First Edition 18 July 2022; final version published online 7 September 2022. DOI 10.1182/bloodadvances.2022007990.

*T.M.H. and M.J.M. contributed equally to this study.

Presented in part at the 62nd annual meeting of the American Society of Hematology, 5-8 December 2020 (virtual meeting).

The data in the study are not publicly available. Data sharing policies and the process to request the data that support the findings of this study can be found on the LEO Cohort website: <https://leocohort.org/>.

The full-text version of this article contains a data supplement.

© 2022 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.

Introduction

Indolent B-cell lymphomas are a group of neoplastic disorders that account for approximately 35% to 45% of non-Hodgkin lymphomas in the Western world.¹⁻⁴ They are clinically indolent but pathologically diverse and are composed of follicular lymphoma (FL), marginal zone lymphoma (MZL, including nodal MZL [NMZL], extranodal MZL [EMZL], and splenic MZL [SMZL]), lymphoplasmacytic lymphoma (LPL)/Waldenström macroglobulinemia (WM), and small lymphocytic lymphoma (SLL)/chronic lymphocytic leukemia (CLL).^{5,6} The overall prognosis is favorable for most patients, but some have an aggressive disease course associated with early progression, relapse, or histologic transformation.^{5,7} Advances in molecular pathology and the introduction of anti-CD20 monoclonal antibodies have significantly impacted the outcomes of these patients.^{8,9} Despite therapeutic advances, lymphoma remains the leading cause of death (COD) in patients with FL.¹⁰ Similarly, in patients with CLL/SLL, deaths caused by the underlying disease and disease-related complications are the principal CODs in the rituximab era.^{11,12}

Prospective data on cause-specific mortality are limited for other indolent B-cell lymphomas. The initial studies, published between 1998 and 2000, reported modest survival outcomes in patients with NMZL with a 5-year overall survival (OS) estimate of 55% to 57%.¹³⁻¹⁶ The survival outcomes of NMZL have improved significantly over the last 2 decades, with the 5-year OS rate ranging from 70% to 90%.¹⁶⁻²² However, OS estimates do not provide specific information about the incidence of death from lymphoma or other causes. An analysis from the Surveillance, Epidemiology, and End Results (SEER) cancer registry database of patients aged ≥ 66 years and diagnosed from 2004 to 2013 showed higher non-lymphoma-related deaths than deaths secondary to lymphoma-related causes in patients with MZL, but mortality rates of different subtypes of MZL such as EMZL, NMZL, and SMZL were not separately reported.²³ Moreover, the existing mortality data for LPL/WM are somewhat limited and conflicting. The data from the US population-based cancer registries showed higher rates of non-lymphoma-related deaths vs lymphoma-related deaths, whereas the study of patients with symptomatic WM by the Greek Myeloma Study Group showed higher WM-related deaths than non-WM-related deaths.^{24,25} The majority of these studies were constrained to retrospective study design and registry database analyses primarily focusing on survival outcomes.

We previously identified in a cohort of patients from our University of Iowa/Mayo Clinic Lymphoma Specialized Program of Research Excellence (SPORE) Molecular Epidemiology Resource (MER) that survival in non-FL low-grade B-cell lymphomas (LGBCL) was comparable to that of the general population for patients who did not progress, relapse, or require retreatment within 12 months of diagnosis.⁵ Conversely, early progression or retreatment of disease was associated with inferior postprogression survival.⁵ Similar results have been observed in a cohort of patients with MZL from the FIL-NF10 study and from a cohort of patients with mucosa-associated lymphoid tissue (MALT) lymphoma from the IELSG-19 clinical trial.^{26,27} In addition, early relapse was highly associated with lymphoma-related death in a cohort of patients with FL from the MER and Lyon, France, but it is unknown how early events impact the cause of death in other indolent B-cell lymphomas.¹⁰ Although there are various known clinicopathologic characteristics that are

predictive of survival, factors related to COD have not been well studied in patients with LGBCL.^{7,18,21,26-31} Moreover, characterization of CODs in patients with LGBCL is important for delivering comprehensive care from counseling to intervention beyond lymphoma and its therapies that could improve their survival. Thus, we performed a detailed examination of COD in the cohort of patients with LGBCL prospectively enrolled in the MER.

Methods

Patient selection

The Mayo Clinic institutional review board reviewed and approved the study. All patients provided informed consent to enroll in the MER of the University of Iowa/Mayo Clinic Lymphoma SPORE.³² The MER is a prospective cohort study of lymphoma outcomes established in 2002 and includes adult patients (≥ 18 years) who are residents of the United States with newly diagnosed lymphoma (within 9 months of diagnosis). Newly diagnosed patients enrolled between 2002 and 2015 were eligible for this study. We included the following histopathologic diagnoses: NMZL; EMZL; SMZL; LPL/WM; and low grade B-cell lymphoma, unclassifiable (LGBCL-U).⁵ Patients with transformation and/or concomitant diffuse large B-cell lymphoma or other aggressive B-cell lymphoma at diagnosis were excluded.

Demographic, clinical, and pathologic data were abstracted using a standard protocol. Pathologic confirmation was done centrally by MER-affiliated expert hematopathologists using current World Health Organization criteria at the time of diagnosis. Participants were contacted prospectively every 6 months for the initial 3 years and then annually. Transformation was defined as the development of biopsy-confirmed diffuse large B-cell lymphoma or high-grade B-cell lymphoma during the follow-up period. Disease progression, retreatment, transformation, and deaths were validated by medical record review. The International Prognostic Index (IPI), Follicular Lymphoma International Prognostic Index (FLIPI), and MALT-IPI were incorporated in the study based on their prognostic utility in patients with LGBCL.^{5,33-35} COD was determined via a review of death certificate copy and/or medical records by MER physicians using a standard protocol and classified as the result of lymphoma (progression or transformation), treatment, unrelated cancer, other causes, or unknown. Treatment-related mortality was broadly defined and further classified into infection, cardiac, or secondary myelodysplastic syndrome/acute myeloid leukemia.

Statistical analyses

Event-free survival (EFS) was defined as the time from diagnosis to the first of progression, relapse, transformation, initiation of a new line of treatment for lack of efficacy, or death from any cause. The cut-point EFS24 was defined based on EFS status at 24 months from diagnosis. Early event was defined as a nondeath event within 24 months of diagnosis (EFS24). All-cause survival was defined as the time from diagnosis until death from any cause or last known follow-up for those alive. COD was first examined by the 5 major categories (lymphoma, treatment, unrelated cancer, other causes, or unknown) and subsequently collapsed into 3 groups for analysis as per previous publication; lymphoma-related (defined as lymphoma or treatment related), unrelated (other malignancies and other causes), and unknown.¹⁰ If COD was unclear, consensus opinion was obtained from 2 other investigators. All-cause survival was summarized by Kaplan-Meier curves. Cumulative incidence for the competing risks of

COD and tests of equality for COD between groups were calculated using the `cuminc` function from the `cmprsk` package in R.³⁶ For early event analysis, time to death was defined as the time since the risk defining event (24-month time point for patients who achieved EFS24 and time since the first event for patients who did not achieve EFS24). Survival from transformation was calculated from the date of pathologic confirmation of transformation. All analyses were performed using SAS (SAS/STAT User's Guide, Version 9.4; SAS Institute, Cary, NC) and R (version 4.0.3). 95% confidence intervals (CIs) are reported for point estimates; *P* values are not adjusted for multiple comparisons.

Results

Baseline characteristics and initial management strategies

A total of 822 patients with newly diagnosed LGBCLs enrolled in the MER from 2002 to 2015 were included in this study. Baseline characteristics of the study population are shown in Table 1. The most common subtype was EMZL (*n* = 363; 44%), followed by LGBCL-U (*n* = 204; 25%), LPL/WM (*n* = 91; 11%), SMZL (*n* = 85; 10%), and NMZL (*n* = 79; 10%). The median age at diagnosis was 64 years (range, 18-92 years), with 60% (*n* = 490) of patients at age > 60 years. Most patients (*n* = 501; 63%) had stage III to IV disease. FLIPI risk category was low risk in *n* = 375 patients (46%), whereas 195 patients (24%) had high-risk FLIPI. MALT-IPI categorized patients slightly differently, with 208 patients (25%) in the low-risk category and 238 (29%) in the high-risk category.

The frontline therapeutic strategies for patients with LGBCL are summarized in Table 1 and varied between different subtypes. The most common approach was observation (38%), which ranged from 26% in LPL/WM to 48% in SMZL. Combination immunotherapy was used in 19% (*n* = 155) of patients, ranging from 9% in SMZL to 40% LPL/WM. A total of 110 study patients (13%) initially received rituximab (R) monotherapy with a range of 8% in SMZL to 20% in LPL/WM. Overall, 12% (*n* = 101) of patients were treated only with radiation therapy, with the highest frequency in patients with EMZL (23%) and lowest in SMZL (1%).

At a median follow-up of 8.9 years (range, 0.3-17.9 years), 31 patients (3.8%) had a transformation, and 219 patients (27%) had died. EFS24 by Kaplan-Meier was 79% (95% CI: 76-82). Lymphoma-related death was observed in 65 patients (58 because of progressive lymphoma and 7 because of therapy-related causes). The subtypes for the 7 therapy-related deaths were LPL (*N* = 3), EMZL (*N* = 3), and LGBCL-U (*N* = 1); class of therapy at the time of death was anthracycline-based immunotherapy (*N* = 2), CD20-bendamustine (*N* = 2), Bruton's tyrosine kinase inhibitor (*N* = 1), mechanistic target of rapamycin inhibitor (*N* = 1), and proteasome inhibitor (*N* = 1). Non-lymphoma-related deaths occurred in 112 patients (51.1%), and cause of death was unknown in 42 (19.2%) patients. Most common causes for non-lymphoma-related deaths (supplemental Table 1) were medical comorbidities (35%) and other malignancies (35%).

Cumulative incidence and distribution of COD overall and by subtype

Ten-year all-cause OS in the cohort was 73.8% (95% CI: 70.4-77.3; Figure 1A), which ranged from 59.6% in SMZL to 83.3% in

NMZL (Figure 1B). There were 219 deaths with 51% (112 of 219) non-lymphoma-related causes and 30% (65 of 219) lymphoma-related causes; and in 19% (42 of 219), the COD was unknown.

The 10-year estimate for lymphoma-related death in the overall study population was 8.0% (95% CI: 6.2-10.4), which was lower than the non-lymphoma-related death rate of 13.6% (95% CI: 11.2-16.6; Figure 2A; Table 2). COD by subtypes is shown in Figure 2B-F. The highest lymphoma-related death incidences were in LPL/WM (10-year estimate, 19.3%; 95% CI: 11.7-31.8) and LGBCL-U (10-year estimate, 11.0%; 95% CI: 7.0-17.2), and the lowest incidence was in EMZL (10-year estimate, 3.7%; 95% CI: 2.2-6.4; Table 2). The incidence for non-lymphoma-related death was highest in SMZL (10-year estimate, 23.0%; 95% CI: 14.9-35.4), followed by LGBCL-U (10-year estimate, 18.5%; 95% CI: 13.2-25.9); the lowest incidence was observed in LPL/WM (10-year estimate, 8.9%; 95% CI: 4.4-18.3).

Patterns of COD by demographic and clinical characteristics

The patterns of COD by key demographic and clinical characteristics are shown in Table 2. The incidence of both lymphoma-related and non-lymphoma-related deaths increased with age at diagnosis. The 10-year estimate for lymphoma-related deaths was 4.1% (95% CI: 2.3-7.5) vs 6.8% (95% CI: 4.2-10.9) vs 14.8% (95% CI: 10.5-20.8) in patients diagnosed at age ≤ 60 years vs 61-70 years vs > 70 years, respectively (*P* < .001). The respective 10-year estimate of non-lymphoma-related mortality was 5.5% (95% CI: 3.3-9.3) vs 13.7% (95% CI: 9.6-19.6) vs 24.5% (95% CI: 19.0-31.5; *P* < .001; Figure 3A-C). Notably, the cumulative incidence of non-lymphoma-related deaths was higher than that of lymphoma-related deaths in all age groups. There were no clinically significant differences in either lymphoma-related deaths (10-year estimate, 9.7%; 95% CI: 7.0-13.3 for men vs 6.4%; 95% CI: 4.2-9.7 for women; *P* = .12) or non-lymphoma-related deaths (10-year estimate, 14.6%; 95% CI: 11.3-18.8 for men vs 12.7%; 95% CI: 9.3-17.2 for women; *P* = .06). Cause of death patterns were similar between the subset of patients diagnosed between 2002 and 2008 and the subset of patients diagnosed between 2009 and 2015 (supplemental Figure 3).

The presence of adverse clinical characteristics was broadly associated with an increase in lymphoma-related deaths. Patients with an elevated lactate dehydrogenase (LDH) at diagnosis had significantly higher incidence of lymphoma-related deaths (10-year estimate, 15.8%; 95% CI: 10.3-24.3) compared with those without LDH elevation (6.5%; 95% CI: 4.6-9.2; *P* = .001), with similar rates for non-lymphoma-related deaths (15.4% vs 14.4% at 10 years; *P* = .97). Patients with hemoglobin (HGB) < 12 g/dL had higher incidence of both lymphoma-related deaths (10-year estimate, 13.6%; 95% CI: 9.6-19.4) and non-lymphoma-related deaths (10-year estimate, 19.9%; 95% CI: 14.9-26.6) compared with patients with HGB ≥ 12 g/dL (10-year estimates, 6.1%, 95% CI: 4.1-9.0; *P* = .001, and 11.5%; 95% CI: 8.6-15.4; *P* = .009, respectively). Similarly, patients with stage III to IV disease had a higher incidence of both lymphoma-related deaths (10-year estimate, 11.4%; 95% CI: 8.7-14.9) and non-lymphoma-related deaths (10-year estimate, 15.1%; 95% CI: 12.0-19.1) compared with patients with stage I/II disease (10-year estimate, 2.2%; 95% CI: 0.9-5.4; *P* < .001, and 9.4%; 95% CI: 6.3-14.1; *P* = .013, respectively).

Table 1. Baseline characteristics of patients with LGBCL

Characteristics	EMZL (N = 363)	LGBCL-U (N = 204)	LPL (N = 91)	NMZL (N = 79)	SMZL (N = 85)	Total (N = 822)
Age group, n (%)						
≤60	163 (44.9)	69 (33.8)	37 (40.7)	30 (38.0)	33 (38.8)	332 (40.4)
61-70	105 (28.9)	57 (27.9)	31 (34.1)	32 (40.5)	23 (27.1)	248 (30.2)
70+	95 (26.2)	78 (38.2)	23 (25.3)	17 (21.5)	29 (34.1)	242 (29.4)
Sex, n (%)						
Male	154 (42.4)	119 (58.3)	61 (67.0)	39 (49.4)	41 (48.2)	414 (50.4)
Female	209 (57.6)	85 (41.7)	30 (33.0)	40 (50.6)	44 (51.8)	408 (49.6)
PS group, n (%)						
<2	345 (96.6)	193 (96.0)	82 (92.1)	69 (89.6)	74 (88.1)	763 (94.4)
≥2	12 (3.4)	8 (4.0)	7 (7.9)	8 (10.4)	10 (11.9)	45 (5.6)
Missing	6	3	2	2	1	14
LDH group, n (%)						
≤Normal	265 (88.0)	122 (79.2)	57 (83.8)	46 (76.7)	49 (64.5)	539 (81.8)
>Normal	36 (12.0)	32 (20.8)	11 (16.2)	14 (23.3)	27 (35.5)	120 (18.2)
Missing	62	50	23	19	9	163
HGB group, n (%)						
≥12 g/dL	240 (79.2)	93 (55.4)	26 (32.5)	46 (75.4)	27 (33.3)	432 (62.3)
<12 g/dL	63 (20.8)	75 (44.6)	54 (67.5)	15 (24.6)	54 (66.7)	261 (37.7)
Missing	60	36	11	18	4	129
Ann Arbor stage group, n (%)						
I-II	221 (61.6)	35 (18.4)	10 (11.1)	24 (31.6)	7 (8.4)	297 (37.2)
III-IV	138 (38.4)	155 (81.6)	80 (88.9)	52 (68.4)	76 (91.6)	501 (62.8)
Missing	4	14	1	3	2	24
IPI group, n (%)						
IPI 0-1	234 (64.5)	65 (31.9)	31 (34.1)	30 (38.0)	14 (16.5)	374 (45.5)
IPI 2	72 (19.8)	88 (43.1)	39 (42.9)	36 (45.6)	41 (48.2)	276 (33.6)
IPI 3	46 (12.7)	41 (20.1)	16 (17.6)	9 (11.4)	26 (30.6)	138 (16.8)
IPI 4-5	11 (3.0)	10 (4.9)	5 (5.5)	4 (5.1)	4 (4.7)	34 (4.1)
FLIPI group, n (%)						
FLIPI 0-1	239 (65.8)	68 (33.3)	22 (24.2)	33 (41.8)	13 (15.3)	375 (45.6)
FLIPI 2	90 (24.8)	74 (36.3)	30 (33.0)	31 (39.2)	27 (31.8)	252 (30.7)
FLIPI 3-5	34 (9.4)	62 (30.4)	39 (42.9)	15 (19.0)	45 (52.9)	195 (23.7)
MALTIPI group, n (%)						
MALTIPI 0	153 (42.1)	29 (14.2)	9 (9.9)	14 (17.7)	3 (3.5)	208 (25.3)
MALTIPI 1	150 (41.3)	91 (44.6)	53 (58.2)	45 (57.0)	37 (43.5)	376 (45.7)
MALTIPI 2-3	60 (16.5)	84 (41.2)	29 (31.9)	20 (25.3)	45 (52.9)	238 (29.0)
Initial treatment, n (%)						
Observation	117 (32.2)	95 (46.6)	24 (26.4)	35 (44.3)	41 (48.2)	312 (38.0)
R-Mono therapy	50 (13.8)	27 (13.2)	18 (19.8)	8 (10.1)	7 (8.2)	110 (13.4)
ImmunoChemo therapy	43 (11.8)	44 (21.6)	36 (39.6)	24 (30.4)	8 (9.4)	155 (18.9)
Radiation therapy	82 (22.6)	9 (4.4)	3 (3.3)	6 (7.6)	1 (1.2)	101 (12.3)
Other	71 (19.6)	29 (14.2)	10 (11.0)	6 (7.6)	28 (32.9)	144 (17.5)
Primary cause of death, n (%)						
Related to lymphoma	15 (20.5)	21 (30.4)	17 (54.8)	4 (33.3)	8 (23.5)	65 (29.7)
Not related to lymphoma	43 (58.9)	33 (47.8)	10 (32.3)	7 (58.3)	19 (55.9)	112 (51.1)
Unknown	15 (20.5)	15 (21.7)	4 (12.9)	1 (8.3)	7 (20.6)	42 (19.2)

ECOG PS, Eastern Cooperative Oncology Group Performance Status.

Downloaded from <https://ashpublications.net/bloodadvances/article-pdf/6/1/752/101918436/advancesadv2022007990.pdf> by guest on 04 May 2024




Figure 1. LGBCL OS. (A) Overall study population. (B) Subtype.

Patterns of COD by baseline prognostic indices

The cumulative incidence of lymphoma-related and non-lymphoma-related deaths increased with a higher FLIPI score (score 0-1 vs 2 vs 3-5) with the 10-year rates of 2.3% (95% CI: 1.1-4.8) vs 9.8% (95% CI: 6.4-15.0) vs 16.8% (95% CI: 12.0-23.7) for lymphoma-related and 8.5% (95% CI: 5.7-12.5) vs 14.5% (95% CI: 10.3-20.2) vs 22.3 (95% CI: 16.5-30.2) for non-lymphoma-related deaths, respectively (both $P < .0001$; Table 2; Figure 4). MALT-IPI also showed similar pattern of increasing cumulative incidence in both lymphoma-related and non-lymphoma-related death rates with increasing score but with different cumulative incidence. The 10-year cumulative incidence for lymphoma-related deaths was 1.3% (95% CI: 0.3-5.2) vs 5.4% (95% CI: 3.3-8.7) vs 18.0% (95% CI: 13.4-24.3) in patients with the MALT-IPI group of 0 vs 1 vs 2-3 ($P < .001$); the respective 10-year cumulative incidence for non-lymphoma-related deaths was 3.3% (95% CI: 1.5-7.3) vs 16.0% (95% CI: 12.1-21.1) vs 19.0% (95% CI: 14.3-25.3; $P < .001$; Table 2, supplemental Figure 1A-C). Similar patterns were observed with the IPI (Table 2). Notably, the cumulative incidence of non-lymphoma-related deaths was higher than that of lymphoma-related deaths in all IPI, FLIPI, and MALT-IPI groups.

Patterns of COD by observed outcomes

We then evaluated the pattern of COD based on transformation and EFS24. In patients with transformed disease, the rate of lymphoma-related death was higher than that of non-lymphoma-related death. The 5-year estimate of lymphoma-related death from date of transformation was 34% (95% CI: 20.3-57.9) in the 31 patients with

transformation during the follow-up period, whereas non-lymphoma-related death was 6.5% at 5 years from transformation (95% CI: 1.6-25.3; supplemental Figure 2). The 621 patients who achieved EFS24 had very low rates of lymphoma-related death from achieving EFS24: 5.1% at 10 years (95% CI: 3.3-7.8; Figure 5A). In contrast, the 139 patients who failed to achieve EFS24 had significantly increased incidence of lymphoma-related deaths: 19.1% (95% CI: 12.8-28.5) at 10 years from early event ($P < .001$; Table 2; Figure 5B). However, death from non-lymphoma-related cause was not significantly different between patients who failed to achieve EFS24 (11.0% at 10 years; 95% CI: 6.5-18.7) compared with those who achieved EFS24 (15.3% at 10 years; 95% CI: 12.1-19.2; $P = .37$). Importantly, failing to achieve EFS24 identified a higher incidence of lymphoma-related vs non-lymphoma-related death (19.1% vs 11.0% at 10 years; Figure 5).

Discussion

To our knowledge, this is the largest examination of COD of a prospective cohort of patients with marginal zone, lymphoplasmacytic, or unclassifiable low-grade B-cell lymphomas with complete clinical characteristic, therapeutic, and outcomes data in the rituximab era. The existing literature on CODs in patients with LGBCLs are limited; therefore, our findings can aid in counseling and prognostication of patients.

A major finding from this study is that in contrast to recently reported data in patients with FL,¹⁰ where lymphoma was the most common cause of death during the first decade from diagnosis, the

Table 2. Ten-year risk of death with 95% CI for clinicopathologic characteristics stratified by cause of death

Clinicopathologic characteristics	Lymphoma-related death			Non-lymphoma-related death			Unknown death		
	10-y estimate	95% CI	P	10-y estimate	95% CI	P	10-y estimate	95% CI	P
All	0.080	0.062-0.104		0.136	0.112-0.166		0.045	0.032-0.065	
Age group, y			<.001			<.001			<.001
≤60	0.041	0.023-0.075		0.055	0.033-0.093		0.017	0.007-0.040	
61-70	0.068	0.042-0.109		0.137	0.096-0.196		0.031	0.015-0.065	
70+	0.148	0.105-0.208		0.245	0.190-0.315		0.100	0.064-0.156	
Sex			.122			.060			.184
Male	0.097	0.070-0.133		0.146	0.113-0.188		0.050	0.032-0.078	
Female	0.064	0.042-0.097		0.127	0.093-0.172		0.041	0.023-0.073	
LDH group			.001			.971			.628
≤Normal	0.065	0.046-0.092		0.144	0.114-0.182		0.042	0.026-0.065	
>Normal	0.158	0.103-0.243		0.154	0.095-0.251		0.072	0.033-0.157	
HGB group			.001			.009			.826
≥12 g/dL	0.061	0.041-0.090		0.115	0.086-0.154		0.048	0.030-0.077	
<12 g/dL	0.136	0.096-0.194		0.199	0.149-0.266		0.048	0.027-0.086	
Ann Arbor stage			<.001			.013			.050
I-II	0.022	0.009-0.054		0.094	0.063-0.141		0.031	0.015-0.066	
III-IV	0.114	0.087-0.149		0.151	0.120-0.191		0.056	0.038-0.084	
IPI score			<.001			<.001			.069
0-1	0.038	0.021-0.069		0.081	0.055-0.119		0.028	0.014-0.056	
2	0.093	0.061-0.144		0.159	0.116-0.218		0.054	0.030-0.095	
3	0.147	0.098-0.220		0.195	0.134-0.286		0.060	0.030-0.117	
4-5	0.181	0.086-0.379		0.312	0.169-0.576		0.140	0.041-0.471	
FLIPI group			<.001			<.001			.045
FLIPI 0-1	0.023	0.011-0.048		0.085	0.057-0.125		0.030	0.015-0.059	
FLIPI 2	0.098	0.064-0.150		0.145	0.103-0.202		0.048	0.026-0.089	
FLIPI 3-5	0.168	0.120-0.237		0.223	0.165-0.302		0.073	0.041-0.131	
MALTIPI group			<.001			<.001			.001
MALTIPI 0	0.013	0.003-0.052		0.033	0.015-0.073		0.016	0.005-0.048	
MALTIPI 1	0.054	0.033-0.087		0.160	0.121-0.211		0.038	0.021-0.069	
MALTIPI 2-3	0.180	0.134-0.243		0.190	0.143-0.253		0.084	0.052-0.136	
Initial treatment			.001			.445			.419
Observation	0.075	0.049-0.116		0.160	0.119-0.214		0.035	0.018-0.068	
R-Mono therapy	0.124	0.070-0.219		0.121	0.071-0.209		0.047	0.020-0.112	
ImmunoChemo therapy	0.131	0.082-0.208		0.141	0.089-0.222		0.059	0.030-0.116	
Radiation therapy	0.000	Not applicable		0.073	0.033-0.161		0.026	0.006-0.105	
Other	0.063	0.033-0.119		0.135	0.084-0.217		0.065	0.030-0.140	
EFS 24			<.001			.369			.776
Achieved	0.051	0.033-0.078		0.153	0.121-0.192		0.046	0.030-0.073	
Failed	0.191	0.128-0.285		0.110	0.065-0.187		0.050	0.022-0.113	
Histologic type			<.001			.030			.132
EMZL	0.037	0.022-0.064		0.106	0.076-0.149		0.035	0.019-0.064	
LGBCL-U	0.110	0.070-0.172		0.185	0.132-0.259		0.069	0.037-0.131	
LPL	0.193	0.117-0.318		0.089	0.044-0.183		0.038	0.012-0.117	
NMZL	0.052	0.020-0.135		0.095	0.043-0.208		0.015	0.002-0.107	
SMZL	0.103	0.052-0.204		0.230	0.149-0.354		0.071	0.033-0.155	

Downloaded from <http://ashpublications.net/bloodadvances/article-pdf/6/1/752/101918436/advancesadv2022007990.pdf> by guest on 04 May 2024




Figure 2. Cumulative incidence for the competing risks of cause of death by lymphoma subtype. (A) LGBCL all subtypes. (B) EMZL. (C) LGBCL-U. (D) LPL. (E) NMZL. (F) SMZL.




Figure 3. Cumulative incidence for the competing risks of cause of death by age. (A) Cumulative incidence by cause of death for patients age ≤ 60 years. (B) Cumulative incidence by cause of death for patients ages 61 to 70 years. (C) Cumulative incidence by cause of death for patients age > 70 years.

incidence of non-lymphoma-related deaths was considerably higher than lymphoma-related deaths in patients with nonfollicular LGBCL. The 10-year cumulative risk of mortality from lymphoma-related deaths and non-lymphoma-related deaths was 8.0% and 13.6%, respectively, in the current study compared with 10.3% and 5.1% at 10 years in the patients with FL.¹⁰ The higher non-lymphoma-related death rates seen in patients with NMZL, EMZL, SMZL, and LGBCL-U were similar to the data from the SEER cancer registry of patients with MZL with unspecified subtypes.²³ Additionally, the most common causes of non-lymphoma-related deaths were attributed to medical comorbidities and other malignancies that are encountered routinely in patients without a diagnosis of LGBCL. We did not identify unexpected patterns of non-lymphoma-related death in our clinical review of these patients. Additional follow-up and/or larger studies would be beneficial to facilitate elucidation of particular health comorbidities. The relatively low rate of

lymphoma-related death compared with death from other causes have important clinical implications, especially for patient counseling, estimating prognosis, and management planning. Because the majority of deaths are attributable to non-lymphoma-related causes, the clinical outcomes of these patients may favorably be impacted by addressing medical comorbidities, health maintenance, and increasing physical activity.^{37,38} These patients have intrinsic immune dysfunction rendering them at increased risk for infections and other malignancies, suggesting additional survivorship focus on immunizations, age- and sex-appropriate malignancy screening, and regular full-body skin examinations.³⁹⁻⁴³

Despite advances in the understanding of disease and therapeutic strategies, deaths related to LPL/WM could be considered remarkable and exceeded non-lymphoma-related deaths in the first decade of the rituximab era (10-year cumulative incidence, 19.3%




Figure 4. Cumulative incidence for the competing risks of cause of death according to FLIPI score. (A) Cumulative incidence by cause of death for patients with FLIPI score 0 to 1. (B) Cumulative incidence by cause of death for patients with FLIPI score 2. (C) Cumulative incidence by cause of death for patients with FLIPI score 3 to 5.

vs 8.9%). However, LPL/WM-related death rate of 15% in our cohort is considerably lower than that of the SEER cancer registry data and the Greek Myeloma Study group data that reported a long-term LPL/WM-related death rate of ~20% to 33%.^{23-25,44} The discrepancies in mortality outcomes could be caused in part by different study populations with various disease risk profiles and diverse therapeutic strategies. LPL/WM, however, was the only LGBCL type where lymphoma-related deaths were noted to be higher than non-lymphoma-related deaths, suggesting different epidemiology and biology of disease than other MZL subtypes.

The comparison of these results in LGBCL to a similar analysis in FL provide insights on the spectrum of disease aggressiveness within the broad category of indolent lymphoma. The 10-year all-cause OS rate in the LGBCL cohort was lower than that of the FL cohort (73% vs 80%) despite inclusion of significantly older

patients in LGBCL than the FL cohort (median age, 64 vs 60 and 29% vs 18% age 70+ years, respectively). This may be explained by more indolent biology of LGBCL perhaps with a better overall health status. Similar to patients with FL, age at diagnosis influenced lymphoma-related mortality rates that increased substantially in patients with an older age at diagnosis with the 10-year cumulative mortality rate of 14.8% for those diagnosed at >70 years of age.¹⁰ Likewise, the FLIPI score is strongly associated with lymphoma-related mortality in patients with LGBCL, with the 10-year cumulative mortality rate of 16.8% for those in the FLIPI score 3 to 5 group.¹⁰ However, in contrast to our previous report of patients with FL, we also observed increased risks of non-lymphoma-related death with increasing FLIPI scores in LGBCL. It is plausible that patients with a higher FLIPI score in our cohort were generally older with associated comorbidities, with subsequent increased risks of




Figure 5. Cumulative incidence for the competing risks of cause of death by EFS24 status. (A) Cumulative incidence by cause of death for patients achieving 24 months of event-free survival from diagnosis. (B) Cumulative incidence by cause of death from early event in patients who have progression or retreatment within 24 months of diagnosis.

non-lymphoma-related deaths. Incorporation of genetic and molecular features may lead to development a robust model that is more specific for lymphoma-related death.^{45,46} Nevertheless, these findings also emphasize the need to address medical conditions other than lymphoma and promote health maintenance particularly in patients with high-risk disease.

The most clinically relevant findings in this study is that, similar to FL, patients with early events (failed to achieve EFS24) in our cohort had a markedly increased risk of lymphoma-related deaths compared with those achieving EFS24 (19.1% vs 5.1% at 10 years). This was observed without a corresponding increase in non-lymphoma-related death by EFS24 status and was the only clinical factor to identify a population at risk of lymphoma-related mortality. Early events have previously been associated with increased all-cause mortality in this cohort⁵ and an international prospective registry.²⁶ This study extends those results to confirm that the observed increase in mortality is from lymphoma-related causes. This finding suggests that patients with EFS24 failure may have a different biology that confers a more aggressive tumor type and help design treatment inventions targeted to this population.⁴⁷ Furthermore, although transformation was an infrequent event in our series (N = 31 patients) compared with FL, transformation was associated with a high rate of lymphoma death (34% at 5 years from transformation). Molecular studies of patients with EFS24 failure and/or transformation may provide valuable insights.

The strengths of our study include the prospective cohort design that consecutively enrolled patients with newly diagnosed lymphoma, the systematic collection of clinical data, central pathology review with accurate determination of histopathologic diagnoses, the near-complete follow-up information (particularly for disease progression and CODs), and the validation of mortality events by medical record review. The limitations include the observational study design with management being done at the discretion of the

treating physicians and not driven by a protocol. However, this is more reflective of real-world practice and makes the results generalizable. Moreover, about 25% of our cohort was attributable to LGBCL-U, and further refinement of the diagnosis could be accomplished by additional molecular diagnostic techniques that were not available at the time that some of these patients were accrued (eg, the majority of patients with LPL/WM have *MYD88* L265P mutation that differentiates from other indolent B-cell lymphomas).^{6,48} Although we are able to document the cumulative incidence of lymphoma-related deaths relative to others among patients with LGBCLs, we did not quantify cause-specific risks of death (eg, cardiovascular disease, pulmonary condition, stroke) because of limited case and event numbers. In addition, we were not able to incorporate comorbidity data, which is known to influence survival outcomes. Last, our cohort was not a population-based sample and is limited in terms of diversity with predominantly Whites; therefore, the findings may not be reflective of disease outcomes in the community.

In conclusion, the most common COD in LGBCLs at 10 years was unrelated to lymphoma, in contrast to our previous data on FL and CLL/SLL that reported lymphoma as the most common CODs at 10 years. However, like FL, patients with LGBCLs who failed to achieve EFS24 had significantly increased risk of lymphoma-related deaths. Increased efforts to address other CODs while developing novel therapeutic strategies and clinical and biologic markers that are predictive of early progression are warranted.

Acknowledgments

This work was supported in part through grants from the National Cancer Institute: Lymphoma Epidemiology of Outcomes (U01CA195568) and the University of Iowa/Mayo Clinic Lymphoma SPORE (P50CA097274).

Authorship

Contribution: A.M.T., J.R.C., T.M.H., and M.J.M. conceived and designed the study; all authors collected and/or assembled the data and wrote and reviewed the manuscript; and R.M. and M.J.M. performed statistical analysis.

Conflict-of-interest disclosure: The authors declare no competing financial interests.

ORCID profiles: B.K.L., 0000-0001-5084-0698; Y.W., 0000-0002-1576-8341; A.L.F., 0000-0001-5009-4808; A.J.N., 0000-0002-7904-1651; J.C.V., 0000-0002-2907-0809; U.F., 0000-0001-7891-9891; T.E.W., 0000-0002-4215-6500; J.R.C., 0000-0002-7482-178X; M.J.M., 0000-0002-1867-0526.

Correspondence: Matthew J. Maurer, Department of Quantitative Health Sciences, Mayo Clinic, 200 First St SW, Rochester, MN 55905; e-mail: maurer.matthew@mayo.edu.

References

1. Teras LR, DeSantis CE, Cerhan JR, Morton LM, Jemal A, Flowers CR. 2016 US lymphoid malignancy statistics by World Health Organization subtypes. *CA Cancer J Clin.* 2016;66(6):443-459.
2. Al-Hamadani M, Habermann TM, Cerhan JR, Macon WR, Maurer MJ, Go RS. Non-Hodgkin lymphoma subtype distribution, geodemographic patterns, and survival in the US: a longitudinal analysis of the National Cancer Data Base from 1998 to 2011. *Am J Hematol.* 2015;90(9):790-795.
3. Perry AM, Diebold J, Nathwani BN, et al. Non-Hodgkin lymphoma in the developing world: review of 4539 cases from the International Non-Hodgkin Lymphoma Classification Project. *Haematologica.* 2016;101(10):1244-1250.
4. Shiels MS, Engels EA, Linet MS, et al. The epidemic of non-Hodgkin lymphoma in the United States: disentangling the effect of HIV, 1992-2009. *Am Soc Prev Oncol.* 2013;22(6):1069-1078.
5. Tracy SI, Larson MC, Feldman AL, et al. The utility of prognostic indices, early events, and histological subtypes on predicting outcomes in non-follicular indolent B-cell lymphomas. *Am J Hematol.* 2019;94(6):658-666.
6. Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. *Blood.* 2016;127(20):2375-2390.
7. Casulo C, Friedberg J. Transformation of marginal zone lymphoma (and association with other lymphomas). *Best Pract Res Clin Haematol.* 2017;30(1-2):131-138.
8. Williams ME, Hong F, Gascoyne RD, et al. Rituximab extended schedule or retreatment trial for low tumour burden non-follicular indolent B-cell non-Hodgkin lymphomas: Eastern Cooperative Oncology Group Protocol E4402. *Br J Haematol.* 2016;173(6):867-875.
9. Kahl BS, Hong F, Williams ME, et al. Rituximab extended schedule or re-treatment trial for low-tumor burden follicular lymphoma: eastern cooperative oncology group protocol e4402. *J Clin Oncol.* 2014;32(28):3096-3102.
10. Sarkozy C, Maurer MJ, Link BK, et al. Cause of death in follicular lymphoma in the first decade of the rituximab era: a pooled analysis of French and US cohorts. *J Clin Oncol.* 2019;37(2):144-152.
11. Strati P, Parikh SA, Chaffee KG, et al. Relationship between co-morbidities at diagnosis, survival and ultimate cause of death in patients with chronic lymphocytic leukaemia (CLL): a prospective cohort study. *Br J Haematol.* 2017;178(3):394-402.
12. Wang Y, Achenbach SJ, Rabe KG, et al. Cause of death in patients with newly diagnosed chronic lymphocytic leukemia (CLL) stratified by the CLL-International Prognostic Index. *Blood Cancer J.* 2021;11(8):140.
13. Armitage JO, Weisenburger DD. New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project. *J Clin Oncol.* 1998;16(8):2780-2795.
14. Nathwani BN, Anderson JR, Armitage JO, et al. Marginal zone B-cell lymphoma: a clinical comparison of nodal and mucosa-associated lymphoid tissue types. Non-Hodgkin's Lymphoma Classification Project. *J Clin Oncol.* 1999;17(8):2486-2492.
15. Berger F, Felman P, Thieblemont C, et al. Non-MALT marginal zone B-cell lymphomas: a description of clinical presentation and outcome in 124 patients. *Blood.* 2000;95(6):1950-1956.
16. Thieblemont C, Molina T, Davi F. Optimizing therapy for nodal marginal zone lymphoma. *Blood.* 2016;127(17):2064-2071.
17. Camacho FI, Algara P, Mollejo M, et al. Nodal marginal zone lymphoma: a heterogeneous tumor: a comprehensive analysis of a series of 27 cases. *Am J Surg Pathol.* 2003;27(6):762-771.
18. Arcaini L, Paulli M, Burcheri S, et al; Intergruppo Italiano Linfomi. Primary nodal marginal zone B-cell lymphoma: clinical features and prognostic assessment of a rare disease. *Br J Haematol.* 2007;136(2):301-304.
19. Kojima M, Inagaki H, Motoori T, et al. Clinical implications of nodal marginal zone B-cell lymphoma among Japanese: study of 65 cases. *Cancer Sci.* 2007;98(1):44-49.
20. Orciuolo E, Buda G, Sordi E, et al. 2CdA chemotherapy and rituximab in the treatment of marginal zone lymphoma. *Leuk Res.* 2010;34(2):184-189.
21. Heilgeist A, McClanahan F, Ho AD, Witzens-Harig M. Prognostic value of the Follicular Lymphoma International Prognostic Index score in marginal zone lymphoma: an analysis of clinical presentation and outcome in 144 patients. *Cancer.* 2013;119(1):99-106.
22. Olszewski AJ, Castillo JJ. Survival of patients with marginal zone lymphoma: analysis of the Surveillance, Epidemiology, and End Results database. *Cancer.* 2013;119(3):629-638.

23. Hester LL, Park SI, Wood WA, Stürmer T, Brookhart MA, Lund JL. Cause-specific mortality among Medicare beneficiaries with newly diagnosed non-Hodgkin lymphoma subtypes. *Cancer*. 2019;125(7):1101-1112.
24. Dalal NH, Dores GM, Curtis RE, Linet MS, Morton LM. Cause-specific mortality in individuals with lymphoplasmacytic lymphoma/Waldenström macroglobulinaemia, 2000-2016. *Br J Haematol*. 2020;189(6):1107-1118.
25. Kastritis E, Kyrtsos M-C, Morel P, et al. Competing risk survival analysis in patients with symptomatic Waldenström macroglobulinemia: the impact of disease unrelated mortality and of rituximab-based primary therapy. *Haematologica*. 2015;100(11):e446-e449.
26. Luminari S, Merli M, Rattotti S, et al. Early progression as a predictor of survival in marginal zone lymphomas: an analysis from the FIL-NF10 study. *Blood*. 2019;134(10):798-801.
27. Conconi A, Thieblemont C, Cascione L, et al. Early progression of disease predicts shorter survival in MALT lymphoma patients receiving systemic treatment. *Haematologica*. 2020;105(11):2592-2597.
28. Starr AG, Caimi PF, Fu P, et al. Dual institution experience of nodal marginal zone lymphoma reveals excellent long-term outcomes in the rituximab era. *Br J Haematol*. 2016;175(2):275-280.
29. Alderuccio JP, Reis IM, Habermann TM, et al. Revised-MALT-IPI: a new predictive model that identifies high-risk patients with extranodal marginal zone lymphoma (EMZL). *Blood*. 2019;134(Supplement_1):4010.
30. Montalbán C, Abaira V, Arcaini L, et al; Splenic Marginal Zone Lymphoma Study Group. Risk stratification for splenic marginal zone lymphoma based on haemoglobin concentration, platelet count, high lactate dehydrogenase level and extrahilar lymphadenopathy: development and validation on 593 cases. *Br J Haematol*. 2012;159(2):164-171.
31. Smith A, Crouch S, Lax S, et al. Lymphoma incidence, survival and prevalence 2004-2014: sub-type analyses from the UK's Haematological Malignancy Research Network. *Br J Cancer*. 2015;112(9):1575-1584.
32. Cerhan JR, Link BK, Habermann TM, et al. Cohort profile: the lymphoma specialized program of research excellence (SPORE) molecular epidemiology resource (MER) Cohort Study. *Int J Epidemiol*. 2017;46(6):1753-1754i.
33. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project. *Blood*. 1997;89(11):3909-3918.
34. Solal-Céligny P, Roy P, Colombat P, et al. Follicular lymphoma international prognostic index. *Blood*. 2004;104(5):1258-1265.
35. Thieblemont C, Cascione L, Conconi A, et al. A MALT lymphoma prognostic index. *Blood*. 2017;130(12):1409-1417.
36. Gray RJ. A class of K-sample tests for comparing the cumulative incidence of a competing risk. *Ann Stat*. 1988;16(3):1141-1154.
37. Pophali PA, Ip A, Larson MC, et al. The association of physical activity before and after lymphoma diagnosis with survival outcomes. *Am J Hematol*. 2018;93(12):1543-1550.
38. Abuamsha H, Kadri AN, Hernandez AV. Cardiovascular mortality among patients with non-Hodgkin lymphoma: differences according to lymphoma subtype. *Hematol Oncol*. 2019;37(3):261-269.
39. Travis LB, Curtis RE, Glimelius B, et al. Second cancers among long-term survivors of non-Hodgkin's lymphoma. *J Natl Cancer Inst*. 1993;85(23):1932-1937.
40. Tward JD, Wendland MMM, Shrieve DC, Szabo A, Gaffney DK. The risk of secondary malignancies over 30 years after the treatment of non-Hodgkin lymphoma. *Cancer*. 2006;107(1):108-115.
41. Pirani M, Marcheselli R, Marcheselli L, Bari A, Federico M, Sacchi S. Risk for second malignancies in non-Hodgkin's lymphoma survivors: a meta-analysis. *Ann Oncol*. 2011;22(8):1845-1858.
42. Lorenzo Bermejo J, Pukkala E, Johannesen TB, Sundquist J, Hemminki K. Age-time risk patterns of solid cancers in 60 901 non-Hodgkin lymphoma survivors from Finland, Norway and Sweden. *Br J Haematol*. 2014;164(5):675-683.
43. National Comprehensive Cancer Network. Survivorship. Available at: https://www.nccn.org/professionals/physician_gls/pdf/survivorship.pdf. Accessed 11 August 2021.
44. Castillo JJ, Olszewski AJ, Kanan S, Meid K, Hunter ZR, Treon SP. Overall survival and competing risks of death in patients with Waldenström macroglobulinaemia: an analysis of the Surveillance, Epidemiology and End Results database. *Br J Haematol*. 2015;169(1):81-89.
45. Pillonel V, Juskevicius D, Ng CKY, et al. High-throughput sequencing of nodal marginal zone lymphomas identifies recurrent BRAF mutations. *Leukemia*. 2018;32(11):2412-2426.
46. Spina V, Khiabani H, Messina M, et al. The genetics of nodal marginal zone lymphoma. *Blood*. 2016;128(10):1362-1373.
47. Maurer MJ, Bachy E, Ghesquières H, et al. Early event status informs subsequent outcome in newly diagnosed follicular lymphoma. *Am J Hematol*. 2016;91(11):1096-1101.
48. Treon SP, Xu L, Yang G, et al. MYD88 L265P somatic mutation in Waldenström's macroglobulinemia. *N Engl J Med*. 2012;367(9):826-833.